News

Caplin Point Laboratories Ltd share price inched up 0.08% to Rs 2624.15 after the company`s net profit saw a marginal increase of 3.59% to Rs 179.09 crore, while revenue from operations improved marginally 1.70% to Rs 610.36 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, rising 4.42%. It has improved by 1.16% over last one week and advanced by 11.70% in last one month while the market capitalization of Caplin Point Laboratories Ltd has marginally improved by 3.18% and 29.71% in the same period respectively. Profit before tax (PBT) of Caplin Point Laboratories Ltd stood at Rs 225.22 crore in Q2 FY26, rallying 22.10% year-on-year, and easing 5.52% quarter-on-quarter. EBITDA came in at Rs 180 crore, expanding by 16.37% YoY and gaining 2.30% sequentially. Total expenses posted a minor rise of 0.91% to Rs 418.5 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 107.06 crore, posting a minor increase of 4.85% YoY, while employee benefits expense was at Rs 54.13 crore, ticking higher by 2.87% YoY. For the TTM ended FY26, revenue from operations grew 14.37% to Rs 1937.47 crore, while net profit rose by 17.27% to Rs 541.09 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 49602% to Rs 550.5 crore, and PBT rose 19.91% to Rs 676.78 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 432.37 crore in FY26, as against Rs 318.39 crore in FY25. Caplin Point Laboratories Ltd surged by 24.45% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.

Caplin Point Laboratories Limited announced the re-appointment of Dr. Sridhar Ganesan as Managing Director for a further period of two years, effective August 25, 2026, to August 24, 2028, and the appointment of Mr. D. Muralidharan as Whole-Time Director for two years, effective August 12, 2026, to August 11, 2028, both subject to shareholder approval at the ensuing Annual General Meeting; Mr. Muralidharan will continue as Chief Financial Officer in addition to his Whole-Time Director role.

Caplin Point Laboratories Limited informed the BSE Limited and National Stock Exchange of India Ltd that the record date for the 35th Annual General Meeting (AGM) to be held on September 25, 2026, and for the purpose of payment of final dividend for the financial year 2025-26, if declared, is September 18, 2026.

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2026.

Caplin Steriles (CSL), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) Foscavir Injection from Clinigen Healthcare, (NDA 020068). Foscarnet Sodium Injection is an antiviral medication used to treat CMV retinitis in AIDS patients and HSV infection in immunocompromised individuals. According to IQVIATM (IMS Health), Foscarnet Sodium Injection, (6000 mg/250 mL Infusion Bag) had US sales of approximately $15 million for the 12-month period ending March 2026.